Stay updated with breaking news from Ring Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This is the second of six seminars that the LSHTM Clinical Trials Network is running in 2024 on practical issues in clinical trials. SpeakersDr Anna Last, LSHTMDr Anna Last is a clinical associate professor from LSHTM, who will present on the logistical considerations and preparation required to conduct a cluster randomised trial, using the example of the MATAMAL trial.
A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.
First long-acting HIV prevention product designed specifically for womenApproval paves the way for the monthly ring’s introduction Nearly two-thirds of new adult HIV infections in South Africa occur among womenSILVER SPRING, Md. (March 11, 2022)—The nonprofit International Partnership for Microbicides (IPM) today announced that the monthly dapivirine vaginal ring received
IPM’s New Drug Application for Dapivirine Vaginal Ring to Reduce HIV Risk in Women Accepted for Filing by US Food and Drug Administration IPM’s New Drug Application for Dapivirine Vaginal Ring to Reduce HIV Risk in Women Accepted for Filing by US Food and Drug Administration SILVER SPRING, Md. (March 3, 2021)—The nonprofit International Partnership for Microbicides (IPM) announced today that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for the monthly dapivirine vaginal ring, designed to reduce the risk of HIV-1 infection through vaginal...
Date Time WHO recommends dapivirine vaginal ring as a new choice for HIV prevention for women WHO today recommended that the dapivirine vaginal ring (DPV-VR) may be offered as an additional prevention choice for women at substantial risk[1] of HIV infection as part of combination prevention approaches. The DPV-VR is a female-initiated option to reduce the risk of HIV infection. To properly use the ring, it must be worn inside the vagina for a period of 28 days, after which it should be replaced by a new ring. The ring is made of silicone and is easy to bend and insert. The ring works by relea...